Clascoterone (Breezula) Phase 3 Update: Scalp 1 vs Scalp 2 and What It Means

What the Cosmo Pharmaceuticals Scalp 1 (5.39x) and Scalp 2 (1.68x) Phase 3 readouts actually show for clascoterone in male hair loss, and where the topical AR antagonist sits relative to RU58841, pyrilutamide, finasteride, and minoxidil heading into the 2026 approval window.








